Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

4D Molecular Therapeutics

- PMLiVE

Lilly and MeiraGTx partner in $475m ophthalmology deal

The companies will develop and commercialise therapies for genetic conditions

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

Pfizer/Astellas share positive phase 3 results for Padcev in bladder cancer

Approximately 614,000 people are diagnosed with bladder cancer globally every year

- PMLiVE

Astellas’ Vyloy combination approved by MHRA as first-line gastric cancer treatment

Approximately 6,600 new cases of the disease are diagnosed in the UK every year

- PMLiVE

Merck to expand ophthalmology pipeline with acquisition of EyeBio in deal worth up to $3bn

Merck will gain access to EyeBio’s Restoret to prevent and treat retinal vascular leakage-associated vision loss

- PMLiVE

Astellas signs $962m rare eye disease deal with 4D Molecular Therapeutics

The company will gain the rights to use 4DMT’s gene therapy vector for at least one target

- PMLiVE

Novartis to sell eye-care products to Bausch + Lomb in deal worth up to $2.5bn

The transaction includes the Swiss drugmaker’s anti-inflammatory eye drop Xiidra

- PMLiVE

Astellas to acquire Iveric Bio for approximately $5.9bn

The deal includes the US drugmaker’s lead candidate for geographic atrophy

- PMLiVE

Positive results for Astellas’ zolbetuximab in gastric cancer published in The Lancet

Over one million new cases of gastric cancer were diagnosed globally in 2020

- PMLiVE

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however

AstraZeneca AZ

AZ makes gene therapy move with 4DMT alliance

The new partnership will focus on creating an AAV for lung disease

- PMLiVE

The power of pharma businesses to drive social change

The importance of CSR programmes

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links